Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

Big Five Numbers

Zhengye Biotechnology Holding Limited growth analysis

Start with the long-run numbers that show whether ZYBT compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/A-23.5%-37.6%
Equity
N/AN/A-6.1%-13.3%
Cash
N/AN/A+72.9%+170.5%
ROIC
N/A4.3%-1.8%-17.9%

Analysis

Latest growth is strongest in Cash at +170.5% and weakest in Revenue at -37.6%. Three-year average ROIC is -1.8%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/A-23.5%
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Recent growth has been strongest in Revenue at -23.5% over three years.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where ZYBT earns its revenue, as reported in company filings

This company does not report revenue segments.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$83.0M
+ D&A$26.0M
+ Stock-Based Comp$0
+ Deferred Tax$11.1M
+ Working Capital$44.8M
+ Other Non-Cash$14.4M
= Operating Cash Flow$13.3M
- Capex-$12.6M
= Free Cash Flow$703.0K

Analysis

FY2025 free cash flow is $703.0K. FCF conversion is -0.8% of net income. Operating cash flow was $13.3M, with capex of -$12.6M. The largest bridge item is Working Capital at $44.8M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for ZYBT.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

No analyst ratings available.

Competitor growth

How does Zhengye Biotechnology Holding Limited grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

Surrozen, Inc.

SRZN

$236.36M——-34.7%
-9.6% (5yr)2 analysts

Pro-Dex, Inc.

PDEX

$210.11M+17.4%+13.8%+16.6%
+9.7% (3yr)1 analysts

Cardiol Therapeutics Inc.

CRDL

$120.66M———
—0 analysts

Apyx Medical Corporation

APYX

$118.37M+6.0%+13.8%+5.9%
+12.8% (3yr)3 analysts

Sera Prognostics, Inc.

SERA

$77.99M—+26.5%-32.9%
+225.5% (5yr)1 analysts

Instil Bio, Inc.

TIL

$41.23M———
—1 analysts

Oncolytics Biotech Inc.

ONCY

$37.13M———
—1 analysts

eXoZymes, Inc.

EXOZ

$35.55M———
—

Questions

Growth questions

Common questions about ZYBT's growth, answered from reported and forecast figures.

Is ZYBT growing revenue?

Revenue declined 37.6% year over year, from $186.36M to $116.36M.

Is ZYBT turning growth into profit?

The latest net margin is -60.0%, which shows how much revenue became net income.